Literature DB >> 17723180

Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms.

Komal Raina1, Rajesh Agarwal.   

Abstract

In an effort to develop effective alternative strategies that increase the therapeutic efficacy and minimize the systemic toxicity of chemotherapeutic agents, more efforts are being directed towards the investigation of dietary supplements and other phytotherapeutic agents for their synergistic efficacy in combination with anticancer drugs. One such agent is silibinin, which has shown promising chemopreventive and anticancer effects in various in vitro and in vivo studies. The present review summarizes the effects of the combination of silibinin and chemotherapeutic drugs on the growth inhibition, cell cycle regulation, and apoptosis induction in prostate, breast, and lung cancer systems. Together, the results indicate a synergistic effect of silibinin on growth inhibition, reversal of chemoresistance, apoptosis induction, and a strong increase in G2-M checkpoint arrest when given in combination with these drugs. These results are highly significant with respect to the combined chemotherapy approach, wherein the criteria for combination is that the response has to be synergistic and that the drugs should not share common mechanisms of resistance and not overlap in their major side-effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17723180     DOI: 10.1111/j.1745-7254.2007.00691.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  25 in total

Review 1.  New combination therapies with cell-cycle agents.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Opin Investig Drugs       Date:  2008-06

2.  Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI.

Authors:  Mohadeseh Dastpeyman; Nasrin Motamed; Kayhan Azadmanesh; Ehsan Mostafavi; Vahid Kia; Ali Jahanian-Najafabadi; Mohammad Ali Shokrgozar
Journal:  Med Oncol       Date:  2011-11-19       Impact factor: 3.064

3.  Discovery of novel aromatase inhibitors using a homogeneous time-resolved fluorescence assay.

Authors:  Jin-zi Ji; Ke-jing Lao; Jie Hu; Tao Pang; Zhen-zhou Jiang; Hao-liang Yuan; Jing-shan Miao; Xin Chen; Shan-shan Ning; Hua Xiang; Yu-meng Guo; Ming Yan; Lu-yong Zhang
Journal:  Acta Pharmacol Sin       Date:  2014-07-21       Impact factor: 6.150

4.  Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.

Authors:  Anil K Jain; Komal Raina; Rajesh Agarwal
Journal:  Cell Cycle       Date:  2013-04-25       Impact factor: 4.534

5.  Silibinin Treatment Inhibits the Growth of Hedgehog Inhibitor-Resistant Basal Cell Carcinoma Cells via Targeting EGFR-MAPK-Akt and Hedgehog Signaling.

Authors:  Arpit Dheeraj; Cynthia M Rigby; Cindy L O'Bryant; Chapla Agarwal; Rana P Singh; Gagan Deep; Rajesh Agarwal
Journal:  Photochem Photobiol       Date:  2017-03-06       Impact factor: 3.421

6.  Inhibitory effect of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice.

Authors:  Kameswaran Ravichandran; Balaiya Velmurugan; Mallikarjuna Gu; Rana P Singh; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2010-09-07       Impact factor: 12.531

7.  Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation.

Authors:  Cynthia Tilley; Gagan Deep; Chapla Agarwal; Michael F Wempe; David Biedermann; Kateřina Valentová; Vladimir Kren; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2014-12-09       Impact factor: 4.784

8.  Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators.

Authors:  Samiha Mateen; Alpna Tyagi; Chapla Agarwal; Rana P Singh; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2010-03       Impact factor: 4.784

9.  Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.

Authors:  Samiha Mateen; Komal Raina; Anil K Jain; Chapla Agarwal; Daniel Chan; Rajesh Agarwal
Journal:  Epigenetics       Date:  2012-09-10       Impact factor: 4.528

10.  Inhibition of hTERT Gene Expression by Silibinin-Loaded PLGA-PEG-Fe3O4 in T47D Breast Cancer Cell Line.

Authors:  Zohreh Ebrahimnezhad; Nosratollah Zarghami; Manoutchehr Keyhani; Soumaye Amirsaadat; Abolfazl Akbarzadeh; Mohammad Rahmati; Zohreh Mohammad Taheri; Kazem Nejati-Koshki
Journal:  Bioimpacts       Date:  2013-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.